3B BlackBio Dx diagnostic kits made up 94% of H1 revenue

3B BlackBio Dx Limited reported Rs 77.08 crore of diagnostic-kits revenue in the half year ended 30 September 2026, or about 94% of Rs 81.77 crore in total segment revenue, while agrochemicals recorded a Rs 6.78 lakh segment loss before interest and tax. The filing identifies agrochemicals and molecular diagnostic kits as its two reportable business segments.

How dependent was 3B BlackBio Dx on diagnostic kits in H1?

3B BlackBio Dx derived Rs 77.08 crore, or roughly 94.3%, of its Rs 81.77 crore total segment revenue from diagnostic kits in the half year ended 30 September 2026. Agrochemicals supplied the remaining Rs 4.59 crore, or roughly 5.6%, based on the segment figures disclosed for the two businesses.

Diagnostic-kits revenue increased by Rs 26.69 crore from Rs 50.39 crore in the half year ended 30 September 2025. Agrochemicals revenue, in contrast, decreased by Rs 1.16 crore from Rs 5.75 crore. Total income from operations across the two segments rose by Rs 25.63 crore from Rs 56.14 crore to Rs 81.77 crore.

The filing separately presents consolidated total income of Rs 67.22 crore for the half year ended 30 September 2026, compared with Rs 56.50 crore a year earlier. It does not provide a reconciliation between that consolidated total-income line and the Rs 81.77 crore total income from operations reported in the segment table, so the two measures are not directly comparable from the disclosed information.

Why did 3B BlackBio Dx's agrochemicals segment report a loss?

3B BlackBio Dx's agrochemicals segment reported a Rs 6.78 lakh loss before interest and tax in the half year ended 30 September 2026, compared with a Rs 22.86 lakh profit in the corresponding 2025 half year. Revenue in the segment fell to Rs 4.59 crore from Rs 5.75 crore over the same periods, while the filing does not identify costs, prices, volumes or other reasons for the change in result.

The half-year loss followed a Rs 3,000 segment profit before interest and tax in the quarter ended 30 June 2026 and a Rs 6.82 lakh loss in the quarter ended 30 September 2026. In the September 2025 quarter, agrochemicals had reported a Rs 27.22 lakh profit before interest and tax, compared with the latest September-quarter loss.

Agrochemicals interest expense was Rs 6,000 for the half year ended 30 September 2026, down from Rs 2 lakh in the prior-year half. Because the segment result is stated before interest and tax, the Rs 6.78 lakh loss excludes that interest charge. The filing does not disclose whether the segment's sales pattern reflects seasonality.

How did 3B BlackBio Dx's diagnostic-kits profit compare with agrochemicals?

3B BlackBio Dx reported Rs 37.75 crore of diagnostic-kits segment profit before interest and tax for the half year ended 30 September 2026, up Rs 2.45 crore from Rs 35.30 crore a year earlier. The diagnostic-kits profit exceeded total segment profit of Rs 37.68 crore because agrochemicals reported the Rs 6.78 lakh loss in the same period.

In the quarter ended 30 September 2026, diagnostic-kits segment profit before interest and tax was Rs 24.42 crore, compared with Rs 13.32 crore in the quarter ended 30 June 2026 and Rs 19.38 crore in the September 2025 quarter. Diagnostic-kits revenue was Rs 45.02 crore in the September 2026 quarter, up from Rs 32.06 crore in the preceding quarter.

Interest expense allocated to diagnostic kits was Rs 16.14 lakh in the half year ended 30 September 2026, compared with Rs 2.58 lakh a year earlier. After segment interest, the filing shows profit before tax of Rs 37.52 crore, versus Rs 35.48 crore in the prior-year half; separately, consolidated profit before tax was Rs 42.59 crore in the latest half year.

What do 3B BlackBio Dx's segment assets show?

3B BlackBio Dx reported Rs 374.25 crore of diagnostic-kits assets at 30 September 2026, or about 93.0% of total segment assets of Rs 402.22 crore. Agrochemicals assets were Rs 27.96 crore, while diagnostic-kits assets had risen from Rs 312.92 crore at 30 September 2025 and agrochemicals assets had risen from Rs 27.91 crore.

Diagnostic-kits liabilities were Rs 44.98 crore at 30 September 2026, compared with Rs 34.43 crore a year earlier and Rs 52.82 crore at 30 June 2026. Agrochemicals liabilities were Rs 2.70 crore at 30 September 2026, up from Rs 2.44 crore a year earlier, taking total segment liabilities to Rs 47.68 crore.

The filing reports Rs 329.27 crore of capital employed in diagnostic kits at 30 September 2026, against Rs 278.49 crore a year earlier. Agrochemicals capital employed was Rs 25.26 crore, compared with Rs 25.47 crore at 30 September 2025, while total capital employed across the two segments was Rs 354.53 crore.

Conclusion

3B BlackBio Dx's half-year segment disclosure shows that diagnostic kits generated Rs 77.08 crore of the Rs 81.77 crore total income from operations and Rs 37.75 crore of segment profit before interest and tax. Agrochemicals contributed Rs 4.59 crore of revenue but moved from a Rs 22.86 lakh profit in the prior-year half to a Rs 6.78 lakh loss.

The next results will show whether agrochemicals improves on its Rs 6.82 lakh loss in the quarter ended 30 September 2026 and whether diagnostic-kits revenue remains near the Rs 45.02 crore reported in that quarter. Future disclosures may also clarify the difference between Rs 81.77 crore of segment income from operations and Rs 67.22 crore of consolidated total income for the latest half year, for which this filing gives no reconciliation.